Cracking the code of drug resistance in EGFR-mutant lung cancer

Cracking the code of drug resistance in EGFR-mutant lung cancer

Unlock the secrets behind why EGFR-mutant lung cancer outsmarts targeted therapies like osimertinib—and discover how cutting-edge CRISPR-engineered models are paving the way for smarter, longer-lasting treatments. Join the race to outwit cancer’s resistance and transform patient outcomes forever!

Europe’s quantum leap: industrialising neutral atom technology

Europe’s quantum leap industrialising neutral atom technology

Europe is pioneering the quantum revolution with Q-PLANET, a €250 million initiative turning delicate neutral atom experiments into reliable, industrial-scale products. Discover how this bold move is setting the stage for scalable quantum computing and sensing across the continent!